Lung Cancer Prediction and Uses Thereof
AssigneeSomaLogic Operating Co., Inc.
InventorsLeigh Alexander, Clare Paterson, Rachel M. Ostroff, Yolanda Hagar, Natasha Kureshi
Life of this patent
Estimating the term…
Abstract
The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for evaluating and predicting lung cancer risk. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to estimate or determine lung cancer risk. In another aspect, methods are provided for evaluating and predicting lung cancer risk in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.
Claims96
A method comprising:
- a) measuring the level of PSP-94 protein and the level of at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, HE4, PH, FUT5 and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PSP-94 and the level of the at least one, two, three, four, five, or six proteins.
A method comprising:
- a) measuring the level of PH protein and the level of at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, HE4, PSP-94, FUT5 and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PH and the level of the at least one, two, three, four, five, or six proteins.
A method comprising:
- a) measuring the level of FUT5 protein and the level of at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, HE4, PSP-94, PH and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of FUT5 and the level of the at least one, two, three, four, five, or six proteins.
A method comprising:
- a) measuring the level of CRLF1 protein and the level of at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, HE4, PSP-94, PH and FUT5 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of CRLF1 and the level of the at least one, two, three, four, five, or six proteins.
A method comprising:
- a) contacting a sample from a human subject with a set of capture reagents, wherein each capture reagent has affinity for a different protein of the set of proteins comprising PSP-94 protein, and at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, HE4, PH, FUT5 and CRLF1;
- and
- b) measuring the level of each protein of the set of proteins with the set of capture reagents.
A method comprising:
- a) contacting a sample from a human subject with a set of capture reagents, wherein each capture reagent has affinity for a different protein of the set of proteins comprising PH protein, and at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, HE4, PSP-94, FUT5 and CRLF1;
- and
- b) measuring the level of each protein of the set of proteins with the set of capture reagents.
A method comprising:
- a) contacting a sample from a human subject with a set of capture reagents, wherein each capture reagent has affinity for a different protein of the set of proteins comprising FUT5 protein, and at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, HE4, PSP-94, PH and CRLF1;
- and
- b) measuring the level of each protein of the set of proteins with the set of capture reagents.
A method comprising:
- a) contacting a sample from a human subject with a set of capture reagents, wherein each capture reagent has affinity for a different protein of the set of proteins comprising CRLF1 protein, and at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, HE4, PSP-94, PH and FUT5;
- and
- b) measuring the level of each protein of the set of proteins with the set of capture reagents.
A method comprising:
- a) contacting a sample from a human subject with two capture reagents, wherein one capture reagent has affinity for a PSP-94 protein and the second capture reagent has affinity for a PH protein;
- and
- b) measuring the level of each protein with the two capture reagents.
A method comprising:
- a) contacting a sample from a human subject with two capture reagents, wherein one capture reagent has affinity for a PSP-94 protein and the second capture reagent has affinity for a FUT5 protein;
- and
- b) measuring the level of each protein with the two capture reagents.
A method comprising:
- a) contacting a sample from a human subject with two capture reagents, wherein one capture reagent has affinity for a PSP-94 protein and the second capture reagent has affinity for a CRLF1 protein;
- and
- b) measuring the level of each protein with the two capture reagents.
A method comprising:
- a) contacting a sample from a human subject with two capture reagents, wherein one capture reagent has affinity for a PH protein and the second capture reagent has affinity for a FUT5 protein;
- and
- b) measuring the level of each protein with the two capture reagents.
A method comprising:
- a) contacting a sample from a human subject with two capture reagents, wherein one capture reagent has affinity for a PH protein and the second capture reagent has affinity for a CRLF1 protein;
- and
- b) measuring the level of each protein with the two capture reagents.
A method comprising:
- a) contacting a sample from a human subject with two capture reagents, wherein one capture reagent has affinity for a FUT5 protein and the second capture reagent has affinity for a CRLF1 protein;
- and
- b) measuring the level of each protein with the two capture reagents.
A method comprising:
- a) measuring the level of PSP-94 and PH in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PSP-94 and PH.
A method comprising:
- a) measuring the level of PSP-94 and FUT5 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PSP-94 and FUT5.
A method comprising:
- a) measuring the level of PSP-94 and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PSP-94 and CRLF1.
A method comprising:
- a) measuring the level of PH and FUT5 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PH and FUT5.
A method comprising:
- a) measuring the level of PH and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PH and CRLF1.
A method comprising:
- a) measuring the level of FUT5 and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of FUT5 and CRLF1.
A method comprising:
- a) contacting a sample from a human subject with three capture reagents, wherein each of the three capture reagents has affinity for a protein selected from PSP-94, PH, and FUT5;
- and
- b) measuring the level of each protein with the three capture reagents.
A method comprising:
- a) contacting a sample from a human subject with three capture reagents, wherein each of the three capture reagents has affinity for a protein selected from PSP-94, PH, and CRLF1;
- and
- b) measuring the level of each protein with the three capture reagents.
A method comprising:
- a) contacting a sample from a human subject with three capture reagents, wherein each of the three capture reagents has affinity for a protein selected from PH, FUT5, and CRLF1;
- and
- b) measuring the level of each protein with the three capture reagents.
A method comprising:
- a) contacting a sample from a human subject with three capture reagents, wherein each of the three capture reagents has affinity for a protein selected from FUT5, CRLF1, and PSP-94;
- and
- b) measuring the level of each protein with the three capture reagents.
A method comprising:
- a) measuring the level of PSP-94, PH, and FUT5 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PSP-94, PH, and FUT5.
A method comprising:
- a) measuring the level of PSP-94, PH, and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PSP-94, PH, and CRLF1.
A method comprising:
- a) measuring the level of PH, FUT5, and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of PH, FUT5, and CRLF1.
A method comprising:
- a) measuring the level of FUT5;
- CRLF1, and PSP-94 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of FUT5;
- CRLF1, and PSP-94.
A method comprising:
- a) measuring the level of at least three, four, five, six, or seven proteins selected from the group consisting of MMP-12, SP-D, HE4, PSP-94, PH, FUT5 and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of the at least three, four, five, six, or seven proteins.
A method comprising:
- a) contacting a sample from a human subject with a set of capture reagents, wherein each capture reagent has affinity for a different protein of the set of proteins comprising at least three, four, five, six, or seven proteins selected from the group consisting of MMP-12, SP-D, HE4, PSP-94, PH, FUT5 and CRLF1 in a sample from a human subject;
- and
- b) measuring the level of each protein of the set of proteins with the set of capture reagents.
A method comprising:
- a) measuring the level of MMP-12 protein, and the level of at least one, two, three, four, five, or six proteins selected from the group consisting of SP-D, HE4, PSP-94, PH, FUT5 and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of MMP-12 and the level of the at least one, two, three, four, five, or six, proteins.
A method comprising:
- a) measuring the level of SP-D protein, and the level of at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, HE4, PSP-94, PH, FUT5 and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of SP-D and the level of the at least one, two, three, four, five, six, seven, eight, or nine proteins.
A method comprising:
- a) measuring the level of HE4 protein, and the level of at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, PSP-94, PH, FUT5 and CRLF1 in a sample from a human subject;
- and
- b) identifying the human subject as being at risk for developing lung cancer based on the level of HE4 and the level of the at least one, two, three, four, five, six, seven, eight, or nine proteins.
A method comprising:
- a) contacting a sample from a human subject with a set of capture reagents, wherein each capture reagent has affinity for a different protein of the set of proteins comprising MMP-12 protein, and at least one, two, three, four, five, or six proteins selected from the group consisting of SP-D, HE4, PSP-94, PH, FUT5 and CRLF1;
- and
- b) measuring the level of each protein of the set of proteins with the set of capture reagents.
A method comprising:
- a) contacting a sample from a human subject with a set of capture reagents, wherein each capture reagent has affinity for a different protein of the set of proteins comprising SP-D protein, and at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, HE4, PSP-94, PH, FUT5 and CRLF1;
- and
- b) measuring the level of each protein of the set of proteins with the set of capture reagents.
A method comprising:
- a) contacting a sample from a human subject with a set of capture reagents, wherein each capture reagent has affinity for a different protein of the set of proteins comprising HE4 protein, and at least one, two, three, four, five, or six proteins selected from the group consisting of MMP-12, SP-D, PSP-94, PH, FUT5 and CRLF1;
- and
- b) measuring the level of each protein of the set of proteins with the set of capture reagents.
The method of any one of the preceding claims, wherein the measuring is performed using mass spectrometry, an aptamer based assay and/or an antibody based assay.
The method of any one of the preceding claims, wherein the sample is selected from blood, plasma, serum or urine.
The method of any one of the preceding claims, wherein the protein levels are used to identify a human subject as being at risk for developing lung cancer.
The method of any one of the preceding claims, wherein the human subject is a current smoker or a former smoker.
The method of any one of the preceding claims, wherein the subject has lung cancer.
The method of any one of the preceding claims, wherein the method provides an area under the curve (AUC) of 0.62, 0.67, 0.68, 0.68, 0.70, 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, or above.
The method of any one of the preceding claims, wherein the method provides an area under the curve (AUC) from about 0.6 to about 0.8, from about 0.61 to about 0.78, from about 0.62 to about 0.76, from about 0.62 to about 0.68, from about 0.67 to about 0.72, from about 0.69 to about 0.74, from about 0.71 to about 0.74, from about 0.73 to about 0.76, or from about 0.74 to about 0.76.
The method of any one of the preceding claims, wherein predicting the risk for developing lung cancer is based on input of the levels of the measured proteins in a statistical model.
The method of any one of the preceding claims, further comprising performing a diagnostic screening.
The method of any one of the preceding claims, wherein the method comprises predicting the risk for developing lung cancer for the purpose of determining a medical insurance premium or life insurance premium.
A kit comprising N protein capture reagents, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7, and wherein at least one of the N protein capture reagents specifically binds to a protein selected from PSP-94, MMP-12, SP-D, HE4, PH, FUT5 and CRLF1.
Dependencies are inferred from the claim text.